The devastating effects of stroke can be irreversible, leading to loss of neurons and even death. However, researchers have made a groundbreaking discovery that may change this grim reality. A team led by Osaka Metropolitan University Associate Professor Hidemitsu Nakajima has developed a revolutionary drug called GAI-17, which inhibits the protein GAPDH involved in cell death.

GAPDH, or glyceraldehyde-3-phosphate dehydrogenase, is a multifunctional protein linked to various debilitating brain and nervous system diseases. The team’s innovative approach was to create an inhibitor that targets this protein, preventing its toxic effects on neurons. When administered to model mice with acute strokes, GAI-17 showed astonishing results: significantly reduced brain cell death and paralysis compared to untreated animals.

The significance of GAI-17 extends far beyond stroke treatment. Experiments revealed no adverse effects on the heart or cerebrovascular system, making it a promising candidate for addressing other intractable neurological diseases, including Alzheimer’s disease. Moreover, the drug demonstrated remarkable efficacy even when administered six hours after a stroke – a critical window that could revolutionize stroke care.

“We believe our GAPDH aggregation inhibitor has the potential to be a single treatment for many debilitating neurological conditions,” Professor Nakajima expressed. “We will continue to explore its effectiveness in various disease models and strive towards creating a healthier, longer-lived society.”

Uncovering the Hidden Culprits Behind Alzheimer’s Disease

For decades, researchers have been trying to understand the root causes of Alzheimer’s disease. While amyloids, such as A-beta and tau proteins, have long been the focus of attention, a new study suggests that these sticky brain plaques may not be the only culprits behind cognitive decline.

Researchers at Johns Hopkins University have made a groundbreaking discovery, identifying over 200 types of misfolded proteins in rats that could contribute to age-related cognitive decline. This finding has significant implications for Alzheimer’s research and opens up new avenues for potential therapeutic targets and treatments.

“We’re seeing hundreds of proteins misfolding in ways that don’t clump together in an amyloid and yet still seem to impact how the brain functions,” said Stephen Fried, an assistant professor of chemistry and protein scientist. “Our research is showing that amyloids are just the tip of the iceberg.”

To reach this conclusion, Fried and his team studied 17 two-year-old rats with varying levels of cognitive impairment. They measured over 2,500 types of protein in the hippocampus, a part of the brain associated with spatial learning and memory. The researchers were able to determine which proteins misfolded for all the rats and are associated with aging in general versus which proteins specifically misfold in cognitively impaired rats.

More than 200 proteins were found to be misfolded in the cognitively impaired rats but maintained their shapes in the cognitively healthy rats. This suggests that some of these misfolded proteins may contribute to cognitive decline, according to the researchers.

Misfolded proteins are unable to carry out tasks necessary for a cell to function properly, so cells have a natural surveillance system that identifies and destroys these misbehaving proteins. However, it appears that some misfolded proteins can escape this surveillance system and still cause problems.

The next step for Fried’s team is to use high-resolution microscopes to get a more detailed picture of what the misfolded proteins look like at the molecular level.

“A lot of us have experienced a loved one or a relative who has become less capable of doing those everyday tasks that require cognitive abilities,” Fried said. “Understanding what’s physically going on in the brain could lead to better treatments and preventive measures.”

This research has significant implications for Alzheimer’s disease, as it suggests that there may be multiple targets for treatment beyond amyloids alone. By understanding the molecular differences between healthy and cognitively impaired brains, researchers can develop more effective treatments and potentially prevent cognitive decline in the first place.

Alzheimer’s disease is a complex condition that affects different parts of the brain in various ways. One key factor in the progression of the disease is the misbehavior of tau proteins, which can lead to toxic clumps forming inside neurons and impairing their function. Researchers have long sought to understand why some areas of the brain are more resilient to Alzheimer’s than others, a phenomenon known as selective vulnerability or resilience.

A recent study by researchers at the University of California, San Francisco (UCSF) has made significant strides in this area by combining advanced mathematical modeling with brain imaging and genetics. The study, published in Brain, identified multiple distinct pathways through which risk genes confer vulnerability or resilience to Alzheimer’s disease.

The researchers developed a model called the extended Network Diffusion Model (eNDM), which predicted where tau protein would spread next based on real-world brain connection data from healthy individuals. By applying this model to brain scans of 196 people at various stages of Alzheimer’s, they were able to identify areas that were resistant or vulnerable to the disease.

The study revealed four distinct types of genes: those that boost tau spread along the brain’s wiring (Network-Aligned Vulnerability), those that promote tau buildup in ways unrelated to connectivity (Network-Independent Vulnerability), those that help protect regions that are otherwise tau hotspots (Network-Aligned Resilience), and those that offer protection outside of the network’s usual path (Network-Independent Resilience).

These findings have significant implications for understanding Alzheimer’s disease and developing potential intervention targets. The study’s lead author, Ashish Raj, PhD, noted that their research offers a “hopeful map forward” in understanding and eventually stopping Alzheimer’s disease.

The researchers also highlighted the importance of considering the different biological functions of genes that respond independently of the network versus those that respond in concert with it. This nuanced approach could lead to more effective strategies for identifying potential intervention targets and developing treatments for Alzheimer’s disease.